Plaque Psoriasis Pipeline Analysis report covers 41 drugs currently in different phases of development. Plaque Psoriasis is the most type of Psoriasis and is a chronic, relapsing, inflammatory and inherited skin disorder. The disease is not life threatening but often intractable to treatment. Symptoms of the disease include appearance ofthe Plaques of red skin mostly covered with lose silver coloured scales, discoloration or pitting of nails and plaques of scales on the scalp. The lesions in the disease may be itchy and sometimes crack down and bleed. In more severe cases plaques may merge into one another merging covering a larger area. Topical medications, phototherapy and systemic prescription medications are generally used for the treatment of plaque psoriasis.
The report provides plaque psoriasis treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are AstraZeneca, Regeneron and Shire among others.
Scope:
By Company
By Phase
By Molecule Type
By Region
By Route of Administration
* There may be changes in final report as per data availability.